- Mauro Guarinieri has nearly two decades of experience addressing HIV/AIDS and issues related to equitable access to h... moreMauro Guarinieri has nearly two decades of experience addressing HIV/AIDS and issues related to equitable access to health and human rights. As Senior Technical Adviser, Community Responses and Drug Use he leverages skills, knowledge and experience of harm reduction organizations and Networks of People Who Use Drugs to support implementation of Global Fund-financed programs. He leads the Secretariat’s work on harm reduction and other Drug Use related issues collaborating across the Secretariat and with external partners. The Senior Advisor takes responsibility for support and technical guidance to ensure community responses and Drug Use considerations are integrated throughout the grant cycle. He works directly with Country Teams in the Grant Management Division providing and assisting with technical support to the new funding model and grant renewal processes, including the technical review of CCM-submitted grant requests and concept notes. He also provides the Global Fund with expert guidance on community responses and Drug Use, keeping staff updated on the best scientific evidence and best program practices in this area; identifying opportunities for reprogramming of existing related grants, and for programming of new related funding; representing the Global Fund in technical related fora and liaising closely with key partners to maximize the Global Fund’s contribution to the fight against HIV/AIDS, TB and malaria He have been working with the Global Fund since 2009, first as a Senior Civil Society Officer and then as a Senior Fund Portfolio Manager, responsible for the delivery of the primary business of the Global Fund, the management of grants leading to the mitigation of the impact of AIDS, tuberculosis and malaria. Before joining The Global Fund, as Senior Technical Advisor in Vietnam under the USAID | Health Policy Initiative, he established working relationships and partnerships with the Government of Vietnam, NGO counterparts, and other stakeholders on advocacy and policy development with a specific emphasis on ARV access for most-at-risk populations. Before HPI, he served as a Senior Program Officer for the International Harm Reduction Program of the Open Society Institute, supervising programs in Russia, Ukraine, Kazakhstan, Kyrgyzstan, Tajikistan, Thailand, Indonesia, and Malaysia. He has an extensive consulting history, having worked with the International AIDS Society, the International AIDS Vaccine Initiative, the International Harm Reduction Development Program, the Eurasian Harm Reduction Network, and others international Organizations. Throughout his career, his leadership has extended to the Boards of many bodies, including the European AIDS Treatment Group (EATG) (Chair: 2004 to 2005), The Global Network of People Living With HIV/AIDS (Chair: 2005 to 2006), the International Steering Committee of the International Treatment Preparedness Coalition, the Global Advisory Group of the Collaborative Fund for HIV/AIDS Treatment Preparedness and the Steering Committee of the Health Gap coalition. He holds memberships in many prominent professional organizations, including the UN reference Group on Injection Drug Use and HIV, in addition to having published an array of articles pertaining to HIV. After joining the Global Fund he supported regional engagement of Civil Society in Global Fund processes and have been deeply involved in developing the Global Fund strategy with a special emphasis on Human Rights and equity in access to health.edit
As in other parts of the developing world access to antiretroviral treatment in the countries of Eastern European and the Newly Independent States (EE/NIS) is still limited. Likewise the treatment advocacy and literacy movement in this... more
As in other parts of the developing world access to antiretroviral treatment in the countries of Eastern European and the Newly Independent States (EE/NIS) is still limited. Likewise the treatment advocacy and literacy movement in this region is still very weak. The European AIDS Treatment Group Europes oldest network on access to treatment issues is currently expanding to these countries in order to assist in the building up of treatment preparedness in the region. (authors)
Research Interests:
Research Interests:
j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / d r u g p o Substance, structure and stigma: Parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods a b s t r... more
j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / d r u g p o Substance, structure and stigma: Parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods a b s t r a c t Background: Parenting and pregnancy in the context of drug use is a contentious topic, high on the policy agenda. Providing effective support to parents who are opioid dependent, through early intervention, access to drug treatment and parenting skills training, is a priority. However, little is known about opioid dependent parents' experiences and understanding of parenting support during the antenatal and post-natal periods. This paper focuses on the position and impact of opioid substitution therapy (OST) in the accounts of parents who were expecting, or who had recently had, a baby in the UK. Methods: Semi-structured qualitative interviews were held with a purposive sample of 19 opioid depend-ent service users (14 female, 5 male). Lon...
Research Interests:
Research Interests:
Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information... more
Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Interests:
Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are understandable concerns over potential harms including the transmission of HIV. However, there have been no previous global reviews of... more
Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are understandable concerns over potential harms including the transmission of HIV. However, there have been no previous global reviews of the extent to which these drugs are injected or levels of HIV among users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline form is available, evidence suggests users are more likely to smoke or inject the drug...
Research Interests:
The global epidemiology of methamphetamine injection: A review of the evidence on use and associations with HIV and other harm
Research Interests:
In recent years, services and options for people with opiate dependence have expanded to include a range of prolonged-release buprenorphine formulations. Although these new options can represent the right solution for some individuals, a... more
In recent years, services and options for people with opiate dependence have expanded to include a range of prolonged-release buprenorphine formulations. Although these new options can represent the right solution for some individuals, a significant risk of a coercive use exists, especially in countries where people who use drugs are highly criminalised and discriminated against. In such contexts, these medications could be used as a means to reduce people’s choice with regard to their bodily integrity and their drug use. In return, this could essentially enforce prohibition and morally-driven ideas of abstinence.
Research Interests:
There is a widespread acknowledgment that successful treatment with highly active antiretroviral therapy (HAART) requires the patient to maintain consistent adherence to the prescribed regimen on a long-term basis. Adherent patients have... more
There is a widespread acknowledgment that successful treatment with highly active antiretroviral therapy (HAART) requires the patient to maintain consistent adherence to the prescribed regimen on a long-term basis. Adherent patients have been shown to have reduced viral loads and increased CD4 counts, live longer, and have better quality-adjusted survival. The consequences of nonadherence are also obvious: poorer adherence leads to inadequate viral suppression and continued disease progression. With the astonishing advances in medical therapeutics during the past two decades, one may expect a similar proliferation of studies of the nature of nonadherence and tests of strategies to help patients overcome it. However, the literature and the know-how concerning interventions to improve adherence are still surprisingly weak. The unique challenges posed by combination therapies for HIV and AIDS require healthcare providers to address the issues created by adherence to complex regimens through multifactorial interventions tailored to patients' needs.